Nieves Lopez-Munoz
Overview
Explore the profile of Nieves Lopez-Munoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Garcia A, Ancos-Pintado R, Garcia-Vicente R, Ortiz-Ruiz A, Arroyo A, Navarro M, et al.
Microbiome
. 2025 Feb;
13(1):56.
PMID: 40022244
Background: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM...
2.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat J, Gonzalez-Calle V, Moreno D, et al.
Blood Adv
. 2024 Nov;
9(3):571-582.
PMID: 39602341
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in...
3.
Zabaleta A, Puig N, Cedena M, Oliver-Caldes A, Perez J, Moreno C, et al.
Am J Hematol
. 2024 Nov;
100(1):93-102.
PMID: 39548827
The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients...
4.
Blanco-Sanchez A, Gil-Manso R, de Nicolas R, Lopez-Munoz N, Colmenares R, Mas R, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335122
Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as "idiopathic". This can be explained by the absence of an evident secondary...
5.
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, et al.
Curr Med Res Opin
. 2024 Aug;
40(9):1597-1603.
PMID: 39129504
Objective: To estimate the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM) treated with 2-4 prior lines of therapy. Methods: Matching...
6.
Martinez-Lopez J, Montesinos P, Lopez-Munoz N, Ayala R, Martinez-Sanchez P, Gorrochategui J, et al.
Med Int (Lond)
. 2024 Jun;
2(2):7.
PMID: 38938528
OPB-111077 is a novel, highly specific oral signal transducer and activator of transcription 3 inhibitor that has exhibited good efficacy against solid and blood cancers, including acute myeloid leukemia (AML),...
7.
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2085-2096.
PMID: 38466644
Purpose: B-cell maturation antigen (BCMA)-chimeric antigen receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated...
8.
Haertle L, Buenache N, Cuesta Hernandez H, Simicek M, Snaurova R, Rapado I, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672481
For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but...
9.
Carreno-Tarragona G, Varghese L, Sebastian E, Galvez E, Marin-Sanchez A, Lopez-Munoz N, et al.
Leukemia
. 2021 Apr;
35(11):3295-3298.
PMID: 33846542
No abstract available.